ID   HLF
AC   CVCL_2947
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN10987769
DR   CCLE; HLF_LIVER
DR   Cell_Model_Passport; SIDM00065
DR   CGH-DB; 9076-4
DR   Cosmic; 945157
DR   Cosmic; 1187332
DR   Cosmic; 1518229
DR   Cosmic; 2023860
DR   Cosmic; 2162527
DR   DepMap; ACH-000393
DR   GEO; GSM887086
DR   GEO; GSM888156
DR   GEO; GSM936758
DR   GEO; GSM1374538
DR   GEO; GSM1669885
DR   IARC_TP53; 2009
DR   JCRB; JCRB0405
DR   LiGeA; CCLE_520
DR   LINCS_HMS; 50015
DR   LINCS_LDP; LCL-1938
DR   Wikidata; Q54889850
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   DOI=10.11418/jtca1981.12.3_221;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=52570;
RX   PubMed=1778766;
RX   PubMed=7874267;
RX   PubMed=8389256;
RX   PubMed=9290701;
RX   PubMed=10523694;
RX   PubMed=12029633;
RX   PubMed=15767549;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=25984343;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 53 hours (PubMed=52570); 27 hours (PubMed=25984343).
CC   Sequence variation: TP53 p.Gly244Ala (c.731G>C) (PubMed=8389256).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=85.67%; East Asian, South=14.33%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 9,11
ST   D5S818: 11
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3099; Hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_1281 ! HLE
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 23
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   DOI=10.11418/jtca1981.12.3_221;
RA   Namba M., Nakabayashi H., Doi I., Sato J., Miyazaki M.;
RT   "Cellular characteristics and utilization of human hepatoma cell lines
RT   which were established in our laboratory and distributed by Japanese
RT   Cancer Research Resources Bank.";
RL   Tissue Cult. Res. Commun. 12:221-227(1993).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=52570; DOI=10.20772/cancersci1959.66.4_385;
RA   Doi I., Namba M., Sato J.;
RT   "Establishment and some biological characteristics of human hepatoma
RT   cell lines.";
RL   Gann 66:385-392(1975).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=7874267; DOI=10.1007/BF02349278;
RA   Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K.,
RA   Yachi A.;
RT   "Expression of cytoskeletal-associated protein tyrosine phosphatase
RT   PTPH1 mRNA in human hepatocellular carcinoma.";
RL   J. Gastroenterol. 29:727-732(1994).
//
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10523694; DOI=10.3892/or.6.6.1267;
RA   Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.;
RT   "Yeast functional assay of the p53 gene status in 11 cell lines and 26
RT   surgical specimens of human hepatocellular carcinoma.";
RL   Oncol. Rep. 6:1267-1271(1999).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y.,
RA   Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218-2218(2013).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//